(Q36614830)

15 August 2017

HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients (English)

1 reference

15 August 2017

P Bruzzi

2

0 references

author name string

L Del Mastro

1

1 reference

15 August 2017

G Nicolò

3

1 reference

15 August 2017

G Cavazzini

4

1 reference

15 August 2017

A Contu

5

1 reference

15 August 2017

M D'Amico

6

1 reference

15 August 2017

A Lavarello

7

1 reference

15 August 2017

F Testore

8

1 reference

15 August 2017

B Castagneto

9

1 reference

15 August 2017

E Aitini

10

1 reference

15 August 2017

L Perdelli

11

1 reference

15 August 2017

C Bighin

12

1 reference

15 August 2017

R Rosso

13

1 reference

15 August 2017

Marco Venturini

14

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 July 2005

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

93

1 reference

15 August 2017

1

1 reference

15 August 2017

7-14

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6602660

15 August 2017

0 references

cites work

Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361477

Traditional and newer pathologic factors.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361477

When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361477

ERBB2 amplification in breast cancer with a high rate of proliferation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361477

Conference summary, Strategic Science symposium. Her-2/neu testing of breast cancer patients in clinical practice.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361477

HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361477

Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361477

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

20 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602660

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer

21 January 2018

1 reference

12 December 2020

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer

1 reference

12 December 2020

Is Her2 of value in identifying patients who particularly benefit from anthracyclines during adjuvant therapy? A qualified yes

1 reference

12 December 2020

Is HER-2/neu a predictor of anthracycline utility? No

1 reference

12 December 2020

HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6602660

1 reference

Dimensions Publication ID

15 August 2017

0 references

1 reference

15 August 2017

PubMed publication ID

15970926

1 reference